Oculis Holding AG (OCS)
(Delayed Data from NSDQ)
$11.93 USD
+0.04 (0.29%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $11.95 +0.02 (0.17%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$11.93 USD
+0.04 (0.29%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $11.95 +0.02 (0.17%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Zacks News
IGM Biosciences, Inc. (IGMS) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
IGM Biosciences (IGMS) delivered earnings and revenue surprises of -2,733.33% and 97.58%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Cytokinetics (CYTK) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of -28.43% and 98.16%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Aadi Bioscience, Inc. (AADI) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Aadi Bioscience (AADI) delivered earnings and revenue surprises of 23.94% and 2.39%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Mirum Pharmaceuticals (MIRM) Surges 7.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Mirum Pharmaceuticals (MIRM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
How Much Upside is Left in Oculis Holding AG (OCS)? Wall Street Analysts Think 152.77%
by Zacks Equity Research
The consensus price target hints at a 152.8% upside potential for Oculis Holding AG (OCS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
What Makes Oculis Holding AG (OCS) a Good Fit for 'Trend Investing'
by Zacks Equity Research
Oculis Holding AG (OCS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Can Oculis Holding AG (OCS) Climb 191.31% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 191.3% upside potential for Oculis Holding AG (OCS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.